CRL

Business profile & competitive position

Charles River Laboratories International, Inc. operates in the Healthcare sector under the Medical – Diagnostics & Research industry. The company is a full-service, non-clinical drug development partner, supporting clients from target identification through non-clinical development and product release. Its operations are organized into three reportable segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions. This structure gives the company broad exposure to preclinical research, safety testing, and outsourced manufacturing support for biopharma clients.

The current profitability metrics, however, do not point to strong near-term pricing power. Net margin is negative at -6.0%, and return on equity (ROE) stands at -7.7%. Negative margins and a negative ROE mean the business is currently consuming capital rather than generating excess returns. While scale, geographic reach, and an integrated service portfolio can be competitive advantages, the latest figures suggest those advantages are not translating into reported profitability right now. Investors should treat any “moat” claims with caution until margins and returns turn positive.

Financial posture

Charles River Laboratories carries a market capitalization of $14.5 billion and trades at a negative P/E ratio of -62.0. A negative P/E reflects the company’s loss position rather than offering a meaningful valuation multiple. With a net margin of -6.0% and ROE of -7.7%, traditional earnings-based valuation tools are essentially impaired; the stock is being priced on expectations of a future earnings recovery rather than on current profit.

The stock’s beta is 1.40, meaning it has been more volatile than the broader market. That higher sensitivity is consistent with a contract-research and diagnostics name tied to biopharma R&D spending, capital allocation decisions, and operating leverage. The financial snapshot therefore shows a large-cap healthcare services company that is currently loss-making and relatively volatile.

Strategic priorities & outlook

The company’s most recent 10-K filing frames its near-term agenda around footprint rationalization, organizational integration, and scientific partnership expansion. Charles River plans to optimize its global footprint by closing or consolidating approximately 12 additional sites over the next two years, principally within the DSA and RMS segments. It is also integrating Discovery Services and Safety Assessment into a single DSA organization, combining the sales force and leadership under one umbrella.

Beyond cost and structure, management says it wants to be the “scientific partner of choice” by delivering a comprehensive, integrated portfolio that accelerates biomedical research and therapeutic innovation. Growth initiatives include further expansion of Biologics Testing Solutions service offerings and facilities in the United States and Europe.

Scale context supports those ambitions: in 2025 total revenue was $4.0 billion, with DSA contributing 59.8%, RMS 21.1%, and Manufacturing 19.1%. The company operates across more than 120 sites in over 20 countries. In January 2026 it acquired certain assets of K.F. (Cambodia) Ltd., a provider of non-human primates, to support DSA supply operations and RMS third-party sales. That acquisition underscores how important research-model sourcing remains to both the safety-assessment and research-models businesses.

Macro & geopolitical exposure

As a Medical – Diagnostics & Research company with global operations, Charles River is exposed to several macro and geopolitical factors. The industry is heavily regulated; GLP and non-GLP safety studies, biologics testing, and manufacturing support all operate under FDA, EMA, and equivalent standards worldwide. Changes in regulatory requirements, inspection intensity, or animal-use restrictions can directly affect operating procedures and costs.

Because the company sources and maintains research models—including non-human primates—it faces supply-chain and geopolitical risks tied to animal health, transportation rules, and cross-border trade policy. Its January 2026 Cambodian acquisition is an example of how research-model supply chains can extend into jurisdictions with distinct political and trade-risk profiles. Currency risk is also relevant, given revenue and costs generated across more than 20 countries. Finally, the broader biopharma funding climate influences demand for outsourced discovery and safety services, making the stock sensitive to trends in venture-capital flows and large-pharma R&D budgets.

Recent developments

Recent headlines show a mix of technical attention, partnership activity, and earnings scheduling. On 2026-10-15, defenseworld.net noted that Charles River’s share price had crossed above its 200-day moving average. On 2026-10-13, businesswire.com reported a collaboration with Magellan Stem Cells to advance stem cell and regenerative medicine development. On 2026-10-09, businesswire.com announced that the company had scheduled its third-quarter 2026 earnings release and conference call. Earlier, on 2026-10-07, zacks.com published a comparative valuation piece asking whether PGNY or CRL was the better value stock right now. None of these items alter the underlying financial posture, but they illustrate current investor focus on technical milestones, new scientific partnerships, and the upcoming quarterly report.

Earnings behavior & post-earnings drift

Charles River’s earnings track record against the official consensus has been exceptionally strong. Over the last eight reported quarters, the company beat estimates every time, for a 100% beat rate, with an average earnings surprise of 9.3%. The most recent four quarters are consistent with that history:

• 2026-08-05: actual EPS $3.02 versus estimate $2.74, a 10.2% surprise; the stock rose 1.84% the next day and 9.07% over the following five trading days.
• 2026-05-07: actual EPS $2.06 versus estimate $1.96, a 5.1% surprise; the stock fell 2.23% the next day and 12.42% over the following five trading days.
• 2026-02-18: actual EPS $2.39 versus estimate $2.33, a 2.6% surprise; the stock rose 3.95% the next day and 6.05% over the following five days.
• 2025-11-05: actual EPS $2.43 versus estimate $2.32, a 4.7% surprise; the stock rose 1.9% the next day and 2.27% over the following five days.

Across those eight quarters, the average 5-day price move after earnings has been 1.24%, classified as an upward post-earnings drift. Still, the May 2026 reaction shows that a beat does not guarantee a positive market response; expectations, guidance, and segment commentary all matter. The next scheduled report is 2026-11-04 before the market open, with an official consensus EPS estimate of $2.97.

For a deeper dive into how institutions are interpreting these fundamentals, technicals, and earnings dynamics, explore the full institutional verdict on Charles River Laboratories.